349 related articles for article (PubMed ID: 31122495)
1. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.
Boxer AL; Qureshi I; Ahlijanian M; Grundman M; Golbe LI; Litvan I; Honig LS; Tuite P; McFarland NR; O'Suilleabhain P; Xie T; Tirucherai GS; Bechtold C; Bordelon Y; Geldmacher DS; Grossman M; Isaacson S; Zesiewicz T; Olsson T; Muralidharan KK; Graham DL; O'Gorman J; Haeberlein SB; Dam T
Lancet Neurol; 2019 Jun; 18(6):549-558. PubMed ID: 31122495
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial.
Höglinger GU; Litvan I; Mendonca N; Wang D; Zheng H; Rendenbach-Mueller B; Lon HK; Jin Z; Fisseha N; Budur K; Gold M; Ryman D; Florian H;
Lancet Neurol; 2021 Mar; 20(3):182-192. PubMed ID: 33609476
[TBL] [Abstract][Full Text] [Related]
3. A randomized, single ascending dose study of intravenous BIIB092 in healthy participants.
Qureshi IA; Tirucherai G; Ahlijanian MK; Kolaitis G; Bechtold C; Grundman M
Alzheimers Dement (N Y); 2018; 4():746-755. PubMed ID: 30581980
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.
Dam T; Boxer AL; Golbe LI; Höglinger GU; Morris HR; Litvan I; Lang AE; Corvol JC; Aiba I; Grundman M; Yang L; Tidemann-Miller B; Kupferman J; Harper K; Kamisoglu K; Wald MJ; Graham DL; Gedney L; O'Gorman J; Haeberlein SB;
Nat Med; 2021 Aug; 27(8):1451-1457. PubMed ID: 34385707
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
[TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study.
Sivapalasingam S; Kamal M; Slim R; Hosain R; Shao W; Stoltz R; Yen J; Pologe LG; Cao Y; Partridge M; Sumner G; Lipsich L
Lancet Infect Dis; 2018 Aug; 18(8):884-893. PubMed ID: 29929783
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
8. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
[TBL] [Abstract][Full Text] [Related]
9. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.
Boxer AL; Lang AE; Grossman M; Knopman DS; Miller BL; Schneider LS; Doody RS; Lees A; Golbe LI; Williams DR; Corvol JC; Ludolph A; Burn D; Lorenzl S; Litvan I; Roberson ED; Höglinger GU; Koestler M; Jack CR; Van Deerlin V; Randolph C; Lobach IV; Heuer HW; Gozes I; Parker L; Whitaker S; Hirman J; Stewart AJ; Gold M; Morimoto BH;
Lancet Neurol; 2014 Jul; 13(7):676-85. PubMed ID: 24873720
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
[TBL] [Abstract][Full Text] [Related]
11. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.
Papp KA; Weinberg MA; Morris A; Reich K
Lancet; 2021 Apr; 397(10284):1564-1575. PubMed ID: 33894834
[TBL] [Abstract][Full Text] [Related]
12. Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial.
Tsai RM; Miller Z; Koestler M; Rojas JC; Ljubenkov PA; Rosen HJ; Rabinovici GD; Fagan AM; Cobigo Y; Brown JA; Jung JI; Hare E; Geldmacher DS; Natelson-Love M; McKinley EC; Luong PN; Chuu EL; Powers R; Mumford P; Wolf A; Wang P; Shamloo M; Miller BL; Roberson ED; Boxer AL
JAMA Neurol; 2020 Feb; 77(2):215-224. PubMed ID: 31710340
[TBL] [Abstract][Full Text] [Related]
13. A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau.
Luca W; Foster K; McClure K; Ahlijanian MK; Jefson M
J Prev Alzheimers Dis; 2024; 11(2):366-374. PubMed ID: 38374743
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study.
Lähdeaho ML; Scheinin M; Vuotikka P; Taavela J; Popp A; Laukkarinen J; Koffert J; Koivurova OP; Pesu M; Kivelä L; Lovró Z; Keisala J; Isola J; Parnes JR; Leon F; Mäki M
Lancet Gastroenterol Hepatol; 2019 Dec; 4(12):948-959. PubMed ID: 31494096
[TBL] [Abstract][Full Text] [Related]
15. TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial.
Yuen MF; Balabanska R; Cottreel E; Chen E; Duan D; Jiang Q; Patil A; Triyatni M; Upmanyu R; Zhu Y; Canducci F; Gane EJ
Lancet Infect Dis; 2023 Apr; 23(4):496-507. PubMed ID: 36509100
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.
Hanna MG; Badrising UA; Benveniste O; Lloyd TE; Needham M; Chinoy H; Aoki M; Machado PM; Liang C; Reardon KA; de Visser M; Ascherman DP; Barohn RJ; Dimachkie MM; Miller JAL; Kissel JT; Oskarsson B; Joyce NC; Van den Bergh P; Baets J; De Bleecker JL; Karam C; David WS; Mirabella M; Nations SP; Jung HH; Pegoraro E; Maggi L; Rodolico C; Filosto M; Shaibani AI; Sivakumar K; Goyal NA; Mori-Yoshimura M; Yamashita S; Suzuki N; Katsuno M; Murata K; Nodera H; Nishino I; Romano CD; Williams VSL; Vissing J; Auberson LZ; Wu M; de Vera A; Papanicolaou DA; Amato AA;
Lancet Neurol; 2019 Sep; 18(9):834-844. PubMed ID: 31397289
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study.
Cellier C; Bouma G; van Gils T; Khater S; Malamut G; Crespo L; Collin P; Green PHR; Crowe SE; Tsuji W; Butz E; Cerf-Bensussan N; Macintyre E; Parnes JR; Leon F; Hermine O; Mulder CJ;
Lancet Gastroenterol Hepatol; 2019 Dec; 4(12):960-970. PubMed ID: 31494097
[TBL] [Abstract][Full Text] [Related]
18. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Meininger V; Genge A; van den Berg LH; Robberecht W; Ludolph A; Chio A; Kim SH; Leigh PN; Kiernan MC; Shefner JM; Desnuelle C; Morrison KE; Petri S; Boswell D; Temple J; Mohindra R; Davies M; Bullman J; Rees P; Lavrov A;
Lancet Neurol; 2017 Mar; 16(3):208-216. PubMed ID: 28139349
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB
Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
